Loading...
OTCM
RGRX
Market cap28kUSD
Jul 15, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Name

RegeneRx Biopharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.49%
Rev. gr., 5y
6.26%
Revenues
77k
0.00%
000272,491240,324168,4120849,5391,511,5721,342,84429,484060,61293,30856,65269,66776,76276,76176,76176,761
Net income
-2m
L-10.15%
-1,659,875-3,326,399-5,454,851-8,266,981-11,178,158-10,636,965-6,493,860-5,023,912-6,007,052-847,002-671,343-2,753,642-5,270,483229,125286,487-1,993,553-1,557,657-1,752,193-1,922,399-1,727,272
CFO
-941k
L-5.01%
-1,649,083-2,950,994-4,459,404-7,220,058-8,807,767-10,570,406-6,151,665-4,996,856-5,419,992-274,187-781,599-1,703,943-525,340-1,068,132-663,085-888,294-1,137,970-1,006,929-990,296-940,718

Profile

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
URL
http://www.regenerx.com/
IPO date
Dec 23, 1986
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
77
0.00%
Cost of revenue
1,479
Unusual Expense (Income)
NOPBT
(1,402)
NOPBT Margin
Operating Taxes
(183)
Tax Rate
NOPAT
(1,402)
Net income
(1,727)
-10.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
43
Long-term debt
1,476
Deferred revenue
1,871
Other long-term liabilities
1,373
Net debt
1,229
Cash flow
Cash from operating activities
(941)
CAPEX
Cash from investing activities
Cash from financing activities
4
FCF
(1,230)
Balance
Cash
291
Long term investments
Excess cash
287
Stockholders' equity
(112,074)
Invested Capital
113,318
ROIC
ROCE
1,094.36%
EV
Common stock shares outstanding
143,550
Price
0.14
-13.19%
Market cap
19,939
-10.08%
EV
21,168
EBITDA
(1,402)
EV/EBITDA
Interest
326
Interest/NOPBT